πŸ”¬Deep Research

URGN β€” UroGen Pharma Ltd Β· catalysts, narrative & risks

Β·17 sourcesURGN forecast β†’

UroGen Pharma Ltd. (NASDAQ: URGN) β€” Research Snapshot as of 2026-10-03

Brief Profile

URGN trades on the NASDAQ and is positioned as a commercial-stage uro-oncology/biotechnology company with two marketed products β€” ZUSDURI (Zusduri) and Jelmyto β€” plus an advancing pipeline [1][8]. The stock closed at roughly $41.40 on October 2, 2026, with a market capitalization near $2.0B [11][13].


Recent Catalysts (roughly July–October 2026)


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’